News
--(BUSINESS WIRE)--Corcept Therapeutics Incorporated ... will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback